Denali Therapeutics Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Denali Therapeutics Inc. (DNLI) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $16.84 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- Denali Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $16.55, a 21.53% decline year-over-year.
- Denali Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $21.09, a 3.74% increase year-over-year.
- Denali Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $20.33, a 26.50% decline year-over-year.
- Denali Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $27.66, a 40.73% decline year-over-year.
- Denali Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $19.57, a 6.00% decline from fiscal 2024.
- Denali Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $20.82, a 24.32% decline from fiscal 2023.
- Denali Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $27.51, a 36.11% decline from fiscal 2022.
- Denali Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $43.06, a 40.29% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.84 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $16.55 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $19.57 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $19.70 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $20.25 10-Q · filed 2025-08-11 | |||
| 2025-03-31 | $21.09 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | $20.82 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $20.30 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $20.25 10-Q · filed 2024-08-01 | |||
| 2024-03-31 | $20.33 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | $27.51 10-K · filed 2024-02-28 | |||
| 2023-09-30 | $27.68 10-Q · filed 2023-11-07 | |||
| 2023-06-30 | $27.68 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $27.66 10-Q · filed 2023-05-08 | |||
| 2022-12-31 | $43.06 10-K · filed 2023-02-27 | |||
| 2022-09-30 | $43.54 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $43.97 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | $46.67 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $72.11 10-K · filed 2022-02-28 | |||
| 2021-09-30 | $73.31 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | $74.50 10-Q · filed 2021-08-04 | |||
| 2021-03-31 | $75.52 10-Q · filed 2021-05-05 | |||
| 2020-12-31 | $26.24 10-K · filed 2021-02-26 | |||
| 2020-09-30 | $25.00 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $24.78 10-Q · filed 2020-08-07 | |||
| 2020-03-31 | $24.63 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | $18.58 10-K · filed 2020-02-27 | |||
| 2019-09-30 | $18.67 10-Q · filed 2019-11-06 | |||
| 2019-06-30 | $18.58 10-Q · filed 2019-08-06 | |||
| 2019-03-31 | $11.60 10-Q · filed 2019-05-08 | |||
| 2018-12-31 | $20.25 10-K · filed 2019-03-12 | |||
| 2018-09-30 | $20.55 10-Q · filed 2018-11-08 | |||
| 2018-06-30 | $21.68 10-Q · filed 2018-08-09 | |||
| 2018-03-31 | $22.10 10-Q · filed 2018-05-11 | |||
| 2017-12-31 | $8.78 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |